Inovalon Results Presentation Deck

Continuous Enhancement & Platform Innovation III inovalon The development of CCA QSI-XLTM, continued enhancement of Data Diagnostics TM, and the acceleration of CCA CARAⓇ, join the ranks of a number of additional technology advancements which are being applied to Inovalon's platform. These are resulting in the developemnt and launch of capabilities such as the Company's Post Acute Care (PAC) Platform, integrated Life Sciences Stack, and array of Client Cloud Access versions of many market-tested offerings. The significiant expansion of capability breadth and depth is providing additional ways to deliver value to clients and market opportunity to Inovalon, but also comes with expenses which show up within the Company's Investment in Innovation as well as in additional cost of revenue expense due to operating capacity preparations and overhead due to expanded platform personnel, related quality oversight proccesses, and project management. Early 2000s HEDIS Advantage™ CARA QSI Star Advantage" Prospective Advantage 11 QSHR OSCL INDICES Data Diagnostics™ QSI-XL™ Quality Spectrum™ Policy 380 Graphic for illustrative purposes only. Not all platform capabilities are shown. Underlying technologies (PORT™, PASS, PCIS, etc.) not displayed. INOV 02 2016 Eamings Presentation Supplement (8.3.16) v1.0.0 10 EHR Interoperability QSI-XL™M CCA INDICES CCA Star Advantage® CCA PAC Platform Current Life Sciences Stack CARAⓇ CCA Prospective Advantage CCA © 2016 by Inovalon. All rights reserved.

View entire presentation